Advertisement

Topics

Search Results for "Sunitinib"

07:34 EST 5th December 2016 | BioPortfolio

Matching Channels

None

Matching News

Adjuvant sunitinib for renal cell carcinoma

Dr Ravaud speaks with ecancertv at ESMO 2016 about results from a one-year trial of sunitinib vs placebo for post-nephrectomy high-risk renal cancer patients. This phase III trial found a longer di...

Sunitinib Potential New Option for Adjuvant Treatment in RCC

Patients with renal cell carcinoma at high risk for recurrence had prolonged disease-free survival when treated with sunitinib compared with placebo.

BRIEF-Exelixis announces positive results from phase 2 CABOSUN trial of Cabozantinib vs Sunitinib

* Cabozantinib met primary endpoint of improving progression-free survival as compared to Sunitinib

Early Intervention Important for Sunitinib-Related Hypertension in RCC

Patients with metastatic renal cell carcinoma treated with sunitinib often experience treatment-related hypertension and require rigorous blood pressure control.

Sunitinib Shows Promise as Adjuvant Therapy in RCC

Patients with renal cancer and a high risk for recurrence after nephrectomy may benefit from adjuvant sunitinib, which showed a disease-free survival benefit in a phase 3 trial. Medscape Medical New...

Pfizer's drug improves survival in kidney cancer study

Pfizer has unveiled results from the Phase 3 S-TRAC clinical trial (Sunitinib Trial as Adjuvant Treatment of Renal Cancer) investigating SUTENT (sunitinib) as adjuvant therapy.

First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal

Monday, October 10th 2016 at 6:15am UTC Late-breaking data to be presented at the ESMO 2016 Congress and Published in The New England Journal of Medicine NEW YORK–(BUSINESS WIRE)– Pfizer I...

Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016

Monday, October 10th 2016 at 6:15am UTC – Cabozantinib met the primary endpoint of improving progression-free survival as compared to sunitinib, decreasing the rate of disease progression or death b...

Matching PubMed Articles

Sunitinib uptake inhibits platelet function in cancer patients.

Sunitinib is an oral tyrosine kinase inhibitor used for cancer treatment. Patients treated with sunitinib are at higher bleeding risk. As tyrosine kinases are essential for platelet signalling, the ef...

The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.

Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mec...

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

To assess the efficacy and tolerability of sunitinib rechallenge in the third-line or later setting in patients with metastatic renal cell carcinoma (mRCC).

Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.

Sunitinib is an orally delivered tyrosine kinase inhibitor that exhibits antiangiogenic effects. FDA has approved sunitinib for the treatment of metastatic renal cell carcinoma. However, its efficacy ...

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.

Sunitinib is a protein tyrosine kinase (PTK) inhibitor that has immune-modulating properties. In this context, peripheral blood mononuclear cells (PBMC), mainly constituted by lymphocytes, could be a ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement